Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Ultragenyx Pharmaceutical Inc. has received a consensus rating of "Moderate Buy" from twelve analysts, with eleven giving a buy rating and one a hold rating, alongside an average price target of $81.50.
• Analyst ratings have varied, with Wells Fargo decreasing their target price from $88.00 to $65.00, and Morgan Stanley reducing their target from $65.00 to $55.00.
• The company's recent earnings showed a better-than-expected performance with a reported EPS of ($1.17), surpassing analyst estimates, and a revenue increase of 13.2% year-over-year.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $81.50.

RARE has been the topic of a number of recent analyst reports. Wells Fargo & Company decreased their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Wedbush reduced their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research report on Monday, July 14th. Morgan Stanley reduced their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Canaccord Genuity Group reduced their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, William Blair assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target on the stock.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $29.00 on Tuesday. The firm's 50-day moving average is $29.49 and its two-hundred day moving average is $34.26. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $60.37. The stock has a market capitalization of $2.79 billion, a P/E ratio of -5.24 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. During the same quarter in the prior year, the company posted ($1.52) earnings per share. Ultragenyx Pharmaceutical's revenue for the quarter was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president directly owned 73,271 shares in the company, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the company. Fred Alger Management LLC raised its holdings in Ultragenyx Pharmaceutical by 12.5% in the first quarter. Fred Alger Management LLC now owns 524,637 shares of the biopharmaceutical company's stock valued at $18,997,000 after acquiring an additional 58,372 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Ultragenyx Pharmaceutical in the first quarter valued at approximately $4,400,000. Millennium Management LLC increased its stake in Ultragenyx Pharmaceutical by 2.2% in the first quarter. Millennium Management LLC now owns 712,393 shares of the biopharmaceutical company's stock valued at $25,796,000 after purchasing an additional 15,157 shares during the last quarter. Knott David M Jr purchased a new position in Ultragenyx Pharmaceutical in the first quarter valued at approximately $1,738,000. Finally, Squarepoint Ops LLC purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $3,702,000. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.